Ramipril vs. Amaryl: side effect and effectiveness comparison (a real world drug study)
Summary:
We compare the side effects and drug effectiveness of Ramipril and Amaryl. The phase IV clinical study is created by eHealthMe based on reports (from sources including the FDA) of 246,773 people who take Ramipril and Amaryl, and is updated regularly.
What is Ramipril?
Ramipril has active ingredients of ramipril. It is often used in high blood pressure. eHealthMe is studying from 147,397 Ramipril users. Check the latest studies of Ramipril.
What is Amaryl?
Amaryl has active ingredients of glimepiride. It is often used in diabetes. eHealthMe is studying from 32,259 Amaryl users. Check the latest studies of Amaryl.
246,773 people who take Ramipril and Amaryl are studied.

Drugs being compared in this study:
- Amaryl (glimepiride)
- Ramipril (ramipril)
Most common side effects of the drugs, overall:
Most common side effects of the drugs, in long term (1+ years) use:
Drug effectiveness:
Ramipril:
- not at all: 1.81 %
- somewhat: 14.54 %
- moderate: 39.47 %
- high: 34.22 %
- very high: 9.96 %
Amaryl:
- not at all: 2.11 %
- somewhat: 19.49 %
- moderate: 40.48 %
- high: 29.0 %
- very high: 8.91 %
Want to compare Ramipril with Amaryl?
- Personalize this study to your gender and age (0-99+)How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related studies
Alternative drugs to, pros and cons of:
Browse all side effects of Ramipril:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Amaryl:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study is based on ramipril and glimepiride (the active ingredients of Ramipril and Amaryl, respectively). Other drugs that have the same active ingredients (e.g. generic drugs or brand names) are also considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Valacyclovir and Metallic Taste for Men aged 60+ - a second ago
- Valacyclovir and Loss Of Taste for Men aged 60+ - a second ago
- Valacyclovir and Dysgeusia for Men aged 60+ - a second ago
- Valacyclovir and Taste - Impaired for Men aged 60+ - 2 seconds ago
- Could Desvenlafaxine cause Joint Pain? - 16 seconds ago
- Could Cyclosporine cause Indigestion? - 17 seconds ago
- Could Apixaban cause Lymphoedema? - 34 seconds ago
- Naprosyn and Posture Abnormal for Women aged 50-59 - 36 seconds ago
- Could Simponi cause Renal Disorder? - 44 seconds ago
- Hydramine and Sjogrens for Women aged 60+ - 47 seconds ago